EWTX · XBRL financial data

Edgewise Therapeutics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EWTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	32,189	54,032	90,905	126,966	151,389
General and administrative	11,026	17,626	23,452	31,866	40,017
Total operating expenses	43,215	71,658	114,357	158,832	191,406
Operating income (loss)	(43,215)	(71,658)	(114,357)	(158,832)	(191,406)
Income tax expense (benefit)	0	0	0	0	4
Net income (loss)	(42,813)	(67,640)	(100,163)	(133,813)	(167,795)
Earnings per share, basic USD per share	(1.14)	(1.26)	(1.57)	(1.45)	(1.63)
Earnings per share, diluted USD per share	(1.14)	(1.26)	(1.57)	(1.45)	(1.63)
Weighted average shares, basic thousands of shares	37,526	53,594	63,724	92,415	102,931
Weighted average shares, diluted thousands of shares	37,526	53,594	63,724	92,415	102,931

Fiscal years (EWTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	15,566	21,993	86,097	41,666	61,148
Prepaid and other current assets	2,984	5,052	8,604	5,313	13,276
Total current assets	283,773	356,999	326,997	475,483	543,385
Property and equipment, net	912	8,533	10,443	9,503	7,831
Right-of-use asset	—	1,318	2,247	1,569	1,387
Total assets	285,233	367,101	340,035	486,817	552,603
Accounts payable	3,843	6,105	4,025	5,579	6,006
Accrued liabilities	3,881	5,840	6,071	7,229	7,920
Total current liabilities	10,521	16,585	16,771	23,860	27,370
Lease liability, non-current	—	3,800	4,434	3,741	2,976
Total liabilities	10,850	20,385	21,205	27,601	30,346
Accumulated deficit	(76,960)	(144,600)	(244,763)	(378,576)	(546,371)
Total stockholders' equity	274,383	346,716	318,830	459,216	522,257
Total liabilities and equity	285,233	367,101	340,035	486,817	552,603
Common shares outstanding (cover page) thousands of shares	49,512	63,262	93,111	95,205	107,271

Fiscal years (EWTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(42,813)	(67,640)	(100,163)	(133,813)	(167,795)
Stock-based compensation	4,404	10,924	17,560	24,712	34,752
Net cash from operating activities	(33,507)	(52,635)	(91,948)	(109,028)	(143,816)
Purchases of property and equipment	668	5,546	5,745	1,312	256
Net cash from investing activities	(242,227)	(70,577)	102,886	(184,656)	(32,790)
Proceeds from issuing common stock	—	129,165	52,618	239,147	187,362
Net cash from financing activities	186,384	129,639	53,166	249,253	196,088
Net change in cash	(89,350)	6,427	64,104	(44,431)	19,482

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Edgewise Therapeutics	68,680	not reported	(78,291)*	109.5M	1.3 quarters	Q3 FY26 10-QSep 30, 2026
Innoviva	581,394	106,120	41,698*	71.1M	—	Q3 FY26 10-QSep 30, 2026
Mannkind	52,929	109,374	(18,371)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Schrodinger	246,983	64,491	(47,578)*	not reported	10.9 quarters	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360,212	266,044	56,669*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47,454	22	(57,410)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	82,727	not reported	(77,495)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Travere Therapeutics	123,542	224,563	98,204*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Adaptive Biotechnologies	75,615	83,902	9,605*	161.9M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.